State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases

By  

Current Clinical Pharmacology, Vol. 4, Iss. 1, 2009-01 ,pp. : 4-37

Bentham Science Publishers

Access to resources Recommend Favorite

Prodrug Strategies in Ocular Drug Delivery

By  

Medicinal Chemistry, Vol. 8, Iss. 4, 2012-07 ,pp. : 753-768

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Metabolism in Ocular Drug Delivery

By  

Current Drug Metabolism, Vol. 5, Iss. 6, 2004-12 ,pp. : 507-515

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of N-Acetylcarnosine in the Treatment of Cataracts

By Babizhayev M.A.  

Drugs in R&D, Vol. 3, Iss. 2, 2002-02 ,pp. : 87-103

Adis International

Access to resources Recommend Favorite

Biomarkers of Oxidative Stress and Cataract. Novel Drug Delivery Therapeutic Strategies Targeting Telomere Reduction and the Expression of Telomerase Activity in the Lens Epithelial Cells with N-Acetylcarnosine Lubricant Eye Drops: Anti-Cataract which Helps to Prevent and Treat Cataracts in the Eyes of Dogs and other Animals

By  

Current Drug Delivery, Vol. 11, Iss. 1, 2014-02 ,pp. : 24-61

Bentham Science Publishers

Access to resources Recommend Favorite